Beyond THC Survey
Are the effects of CBD-rich cannabis and high-THC cannabis noticeably different? If so, how? Patients, collectively, can provide the answers. Take the survey.
Medical Cannabis Research
From an 1843 issue of the Provincial Medical Journal in London, comes this reprint of Dr. William O’Shaughnessy’s report on preparation of hemp in the treatment of pain. “As to the evil sequels so unanimously dwelt on by all writers, these did not appear to me so numerous, so immediate, or so formidable, as many which may be clearly traced to over-indulgence in other powerful stimulants or narcotics-viz, alcohol, opium, or tobacco.”.
Published in 2012, this study concluded that elevation of cannabinoid receptor activity either by pharmacological blockade of the degradation of cannabinoids or by receptor agonists could be a promising strategy for slowing down the progression of brain aging and for alleviating the symptoms of neurodegenerative disorders.
This 2013 review, published in the journal Brain Sciences, focused on numerous experimental studies. They report that the modulation of the endocannabinoid system either by enhancement of the endogenous cannabinoid signaling or by administration of exogenous cannabinergic ligands has beneficial effects during the acute and recovery phases after perinatal brain injury.
This 2014 study published in Lancet Psychiatry recorded clear and consistent associations and dose-response relations between the frequency of adolescent cannabis use and all adverse young adult outcomes. After covariate adjustment, compared with individuals who had never used cannabis, those who were daily users before age 17 years had clear reductions in the odds of high school completion and degree attainment and substantially increased odds of later cannabis dependence, use of other illicit drugs, and suicide attempt.
Osteoarthritis and cannabis – Information comes from scientists in the UK and USA, published in PLOS ONE in 2013. Osteoarthritis pain is challenging to treat, with chronic pain leading to central sensitization. Cannabinoids can help. This data provides new clinically relevant evidence that joint damage and spinal CB2 receptor expression are correlated combined with converging pre-clinical evidence that activation of CB2 receptors inhibits central sensitization and its contribution to the manifestation of chronic OA pain. These findings suggest that targeting CB2 receptors may have therapeutic potential for treating OA pain.
Endocannabinoid Anandamide and breast cancer – more evidence. This 2014 study out of Italy, published in the journal Translational Medicine, found that following anandamide treatment, MDA-MB-231 cells lose their ability to stimulate endothelial cells proliferation in vitro, due to a significant inhibition of all the pro-angiogenic factors produced by these cells. This finding adds another piece of evidence to the anti-tumor efficacy of anandamide in breast cancer.